Research programme: tetrahydrofolate dehydrogenase inhibitors - Promiliad Biopharma/ Spero Therapeutics

Drug Profile

Research programme: tetrahydrofolate dehydrogenase inhibitors - Promiliad Biopharma/ Spero Therapeutics

Alternative Names: Dihydrofolate reductase inhibitors -Promiliad Biopharma/ Spero Therapeutics

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Connecticut
  • Developer Promiliad Biopharma; Spero Therapeutics
  • Class Anti-infectives; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Gram-negative infections; Gram-positive infections; Urinary tract infections

Most Recent Events

  • 08 Mar 2016 9192972 - crosschecked, no update
  • 16 Jan 2016 Early research in Gram-positive infections in USA (PO)
  • 07 Jan 2016 Spero Therapeutics in-licenses Dihydrofolate reductase inhibitor programme from Promiliad Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top